Creative Planning Invests $456,000 in Galapagos NV (NASDAQ:GLPG)

Creative Planning bought a new position in shares of Galapagos NV (NASDAQ:GLPG) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 18,407 shares of the biotechnology company’s stock, valued at approximately $456,000.

A number of other large investors have also modified their holdings of GLPG. Headlands Technologies LLC increased its stake in Galapagos by 949.3% in the 1st quarter. Headlands Technologies LLC now owns 787 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 712 shares in the last quarter. Signaturefd LLC grew its holdings in Galapagos by 48.1% during the 2nd quarter. Signaturefd LLC now owns 3,872 shares of the biotechnology company’s stock valued at $96,000 after buying an additional 1,258 shares during the last quarter. Rhumbline Advisers grew its holdings in Galapagos by 21.6% during the 2nd quarter. Rhumbline Advisers now owns 4,578 shares of the biotechnology company’s stock valued at $113,000 after buying an additional 814 shares during the last quarter. BNP Paribas Financial Markets grew its holdings in Galapagos by 783.6% during the 1st quarter. BNP Paribas Financial Markets now owns 5,328 shares of the biotechnology company’s stock valued at $172,000 after buying an additional 4,725 shares during the last quarter. Finally, XTX Topco Ltd acquired a new stake in Galapagos during the 2nd quarter valued at $284,000. 32.46% of the stock is owned by hedge funds and other institutional investors.

Galapagos Stock Performance

GLPG stock opened at $29.34 on Wednesday. The stock’s fifty day simple moving average is $28.05 and its 200-day simple moving average is $27.90. Galapagos NV has a 52-week low of $24.16 and a 52-week high of $42.46.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. Raymond James cut Galapagos from an “outperform” rating to a “market perform” rating in a report on Friday, August 2nd. Leerink Partnrs upgraded Galapagos to a “hold” rating in a report on Monday, September 9th. Finally, Leerink Partners initiated coverage on Galapagos in a report on Monday, September 9th. They set a “market perform” rating and a $24.00 price objective on the stock. One analyst has rated the stock with a sell rating and five have given a hold rating to the stock. According to MarketBeat.com, Galapagos has a consensus rating of “Hold” and a consensus price target of $31.00.

Galapagos Company Profile

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.